Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Outline of Final Research Achievements |
Allergin-1 is an inhibitory immunoglobulin-like receptor bearing immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic region. Allergin-1 inhibits house dust mite-induced serum IgE elevation, airway eosinophilia, and airway hyperreactivity (AHR), therefore, Allergin-1 may be a target molecule for treatment of allergic asthma. In this proposal, a phospholipid liposome was used to treat the HDM-induced allergic asthma. Because, one of the phospholipid has an ability to bind to Allergin-1. However, in the HDM-induced asthma model, not only Allergin-1-binding phospholipid, but also phosphatidylcholine, which does not bind to Allergin-1 inhibited the AHR.
|